Bafna Mahaveer Chand, Chairman and Managing Director, Bafna Pharmacuticals Limited
Bafna Mahaveer Chand, Chairman and Managing Director, Bafna Pharmacuticals Limited, is a Chemistry Graduate from Madras University and has more than 26 years of experience in the trade of manufacture, export of pharmaceuticals and sale of formulation in Domestic and International Market. He is the main promoter of the company and has started his career as a trainee in Kemko Pharma for a period of one year and thereafter he formed his own proprietary concern and started dealing in pharmaceutical products. He has vast experience in institutional supplies and was instrumental in getting significant supply contracts of the central government, several State Governments (including Andhra Pradesh, Tamil Nadu, Kerala and West Bengal) besides ESI Corporation and supplies to Sri Lanka Ukraine and other countries.
BAFNA started business in 1981 with the embodiment of the noble notion "Quality medicines for the needy suffering millions, at an affordable price". BAFNA was started as a proprietary concern in 1981 by Bafna Mahaveer Chand in the name of BAFNA PHARMACEUTICALS and has been engaged in the business of manufacturing pharmaceutical formulations of Betalactam and Non Betalactam products. During the year 1995, BAFNA PHARMACEUTICALS LIMITED was incorporated and it acquired the entire business of the proprietary concern. The Madhavaram unit is WHO GMP certified and also ISO 9000 certified. The products manufactured in this factory cater to the markets of Srilanka, Ghana and Ukraine.
While speaking to Anurag More of India Infoilne, Mr. Bafna says, "We set our standards and are continuously thriving upwards to redefine our own standards in accomplishing our position as the most preferred one stop source for all product development"
What prospects are you seeing for the pharma industry in India?
Indian pharmaceutical industry has grown leaps and bounds, emerging as a global hub and a destination of choice; several initiatives are successfully taken to bring the Indian industry to the forefront of the global pharma industry. The Indian pharma industry today is among the top ranked research-based pharma industries with wide ranging capabilities in the complex field of drug manufacturing.
Despite the global slowdown, the Indian pharma industry has maintained commendable growth. A highly organized sector, the Indian pharma industry is estimated to grow at the rate of 14% per year. The US$20 billion Indian pharmaceutical industry has been growing at a compounded annual growth rate of 9%. The sector is likely to grow to US$50bn by 2015. It is one of the largest and most advanced among the developing countries. So, the Indian pharma industry is a success story.
Brief us about your products?
Our focus is mainly on lifestyle products. The company presently manufactures 126 formulations under various therapeutic segments such as - anti-infective, antihypertensive, cholesterol lowering agents, analgesic and antipyretic, anthelmintics, appetite stimulants, cough & cold preparations, antiulcerants, hypoglycemics and vitamins etc.
The manufacturing facilities of the company are adaptable i.e. the facilities can produce multiple products using a combination of process.
What would you describe is your core strength?
The MHRA (Medicines and Healthcare Products Regulatory Agency) approval for Bafna Pharmaceuticals has opened gates for the company to market its products in the European market. This certification will act as a catalyst for the organization’s growth. Our undivided concentration is on product development through R&D.
Bafna has a modern plant which meets International quality standards. Given our facility and R&D, we are determined to make a mark.
What would your focus be?
Comment on your exports?We set high standards and are continuously thriving to redefine ourselves. We hope to emerge as one of the most preferred one stop sources for all product development and contract manufacturing activities for the regulated markets and across the pharma value chain.
We have increased exports from 30% of total revenue to 50%. This year we look forward to export seven variations and in the next two years 17 products will be ready for launch in European countries.
We have a very strong presence in Sri Lanka, Africa and CIS regions. Recently we got the approval for our first branded product Olmesartan Medoxomil. With this, we have started directly marketing our own brands in Sri Lanka.
Bafna presently has 336 product licenses and has 72 products registered in various countries such as Sri Lanka, Ukraine, Ghana and Lao. The company has registered a few of its brands in India as well.
Tell us about your manufacturing units?
Are they USFDA approved?The company has a WHO-GMP certified manufacturing facility in Madhavaram, which is a 100% Export Oriented Unit (EOU). The facility at Grantlyon, Chennai is accredited with Medicines and Healthcare Regulatory Agency, UK (MHRA). This accreditation has made Bafna Pharma has opened the gates for exploring markets of the European Union. Apart from this, few innovator companies and few renowned European and Indian companies have audited & approved this site for the contract manufacturing. Our plan is to enter the US market in the next 18 months.
What growth do you see in the Indian pharma industry?
While it is generally believed that the pharma industry is recession proof, the fact of the matter is, people do cut down even on healthcare expenses when faced with an economic crisis. Most Indian companies are therefore building a hybrid portfolio i.e. a presence in more than one sub segments - Generics, NCE, CRAMS, and domestic market, in order to diversify risks emerging from a single segment. This is certainly a good strategy going forward.
The vision of the Department of Pharmaceuticals is to enable Indian pharma industry to play a leading role in the global market and to ensure abundant availability, at reasonable prices within the country, of good quality pharmaceuticals of mass consumption.
Brief us about your R&D initiatives?
With advanced manufacturing equipment, testing instruments and process control facilities, the formulations R&D center is equipped to manufacture new products from laboratory scale to validation batches.
The R&D center has qualified and competent research scientists, who have developed many innovations, to meet the various requirements of the global market.
The R&D facility is designed and equipped to meet the stringent international standards. It will be operational by Q4 FY10.
Any new segments you plan to enter?
We would like to enter into a niche segment like Immunosuppressant. Also, we would like to expand from being present in Antibiotics to drugs in the lifestyle related illness.
What makes you different from other players?
Small size for Flexibility.
Multi product capability
Strong F R and D
Focused Markets
Competitive pricing
Efficient, prompt and friendly customer service
Brief us on your financials. What is the outlook?
Bafna Pharmaceuticals reported a net profit of Rs1.24 crore in the quarter ended September 2009 as against a net loss of Rs 0.24 crore during the quarter ended September 2008. Sales rose 81.51% to Rs 16.88 crore in the quarter ended September 2009 as against Rs 9.30 crore during the previous quarter ended September 2008.
The company posted a profit after tax (PAT) growth of 10.55% amounting to Rs 107 Lakhs in the FY 2008-09, as against a net profit of Rs 120 Lakhs in the previous fiscal year. The company recorded sales amounting to Rs 4525 lakhs during FY09 as against net sales of Rs 4038 lakhs during FY08.
The company aims to achieve a turnover of Rs500 crores by 2013 by focusing on prescription drugs in the ROW market. We also plan to target Contract Manufacturing opportunities and intend to file dossiers in regulated markets.
What will be your future business strategy?
The trend is changing; today the global pharma companies are looking forward to join hands with smaller pharma companies who are quality conscious and have the required approvals. At Bafna, we believe that quality is the road to success and foreseeing that we have got the required GMP certification.
We have also managed to get the MHRA certification for the European markets. Going forward, our strategy would be to maintain and deliver World Class Quality products with competitive pricing coupled with efficient, prompt and friendly customer service.
Which are the countries you export your products to?
At present, we export our products to Sri Lanka, CIS and Africa. We have plans to introduce our own branded generic products in Sri Lankan by early 2010. We hope this will boost our revenues.
What is the promoters' stake?
Any plans of adding or diluting stake?The promoter group is holding close to 60% shareholding and 40% is with the public.
In India medical facilities are still out of reach for many. What suggestions would you give to improve this situation?Rural marketing to the nano level, health cover for all and health literacy are some of the ideas that can improve this situation.
Tell us about your domestic-international mix?
Where do you see more growth?Currently, the revenues from domestic and exports are equal. Going ahead we intend to penetrate deeper into the European markets. We have already acquired six clients in Europe for contract manufacturing and have applied for seven variations. We also plan to introduce more branded products in Sri Lanka and other Asian countries.
What advice would you give those who wish to join this industry/company?
Typically what kind of people would you look for from the B-Schools? Ultra specialization with a good knowledge about all the departments- A task force type. AND EVER WILLING TO LEARN.
What do you think B-Schools need to do to make their students ready for the job?
Compulsory Practice School Training along with the curriculum.
What are your hiring plans etc.?In R&D and other dept we will add more recourse. People are our asset.
Ref: http://www.indiainfoline.com/Research/Recommendations/Default.aspx?ReportNo=878